Deliver logo
Previous Sponsor
Cytiva思拓凡是全球生命科学领域的先行者,在全球40余个国家和地区拥有近10,000名员工,致力于推进未见技术,加速非凡疗法。作为客户可信赖的合作伙伴,Cytiva积极携手学术及转化医学领域研究人员、生物技术开发者和制造商,专注于生物药物、细胞和基因疗法以及以mRNA为代表的一系列创新技术的研究,通过提升药物研发和生物工艺的速度、效率、灵活性和能力,为惠及全球患者开发和生产变革性药物和疗法。
Cytiva is a global life sciences leader that works with academic and translational researchers, developers and manufacturers of biotherapeutics, cell and gene therapies, and new technologies such as mRNA, to enable the delivery of transformative medicines. Cytiva is a trusted expert with nearly 10,000 associates in 40 countries dedicated to customers’ speed, flexibility, capacity and efficiency in drug discovery, research, and manufacturing.
Website:
熙宁生物是一家专业的符合国际GLP&GCP质量管理规范的生物分析实验室,为国内外医药公司提供临床和临床前生物分析(Bioanalysis,BA) 和伴随诊断(Companion Diagnostics,CDx) 产品开发服务。
一站式的生物分析服务包括抗体制备和细胞株构建,样本采集包及实验室手册,符合法规要求的分析方法学的开发和验证,以及样本分析。涵盖药代动力学(PK),药效学(PD),抗药抗体(ADA),中和抗体(NAb),和生物标志物(Biomarker)检测,包括基于流式细胞术(FACS)和基因检测平台(PCR)针对细胞和基因治疗药物的PK, PD分析服务,以及细胞和基因水平的生物标志物检测、二代测序(NGS)服务,组织水平的免疫组化检测服务。 伴随诊断产品开发服务包括LDT方法学开发、CDx产品开发及验证、注册检验、临床试验研究和注册申报,委托生产等。  公司在宁波(熙宁生物)、上海(精翰生物)、和美国新泽西(Accurant Bio)都建有实验室,总面积超过8,000 平方米,科学家团队规模超过300人。>30%有5-15年以上的专业工作经验。
已经和国内外近百家药企和生物科技公司建立了临床和临床前研究的项目合作,涵盖肿瘤免疫、自身免疫等多个热门治疗领域,包含蛋白药物,基因及细胞治疗药物等各类生物大分子,其中双特异性抗体>15个,基因和细胞治疗药物>33个,在研靶点>40个,临床试验>250个。
成功支持国内第一款 I 类新药的Car-T产品-药明巨诺倍诺达(瑞基奥仑赛注射液)的上市。参与《中国药典2015版》“生物样品分析方法验证指导原则”、2021年NMPA《药物免疫原性研究技术指导原则》、及国际上多个行业白皮书的撰写;支持过200多项全球多中心临床试验,100多个各类大分子产品的临床研究,多次成功通过FDA、EMA、OECD、NMPA的审计。
Website:
上海益诺思生物技术股份有限公司成立于2010年,是国药集团下属中国医药工业研究总院有限公司的控股子公司。秉承 “科学引领、质量唯先、诚信敬业、团结互信”的核心价值观,以创新促发展、以质量求生存、以信誉赢客户、以管理创效益,先后通过NMPA的GLP认证、美国FDA的GLP检查、OECD 成员国荷兰政府的GLP认证,AAALAC 认证及美国病理学会的CAP认证等,是一家专业的提供生物医药非临床研究服务为主的综合研发服务(CRO)企业。业务范围覆盖早期成药性评价、非临床药效、非临床药代动力学、非临床安全性研究、临床生物分析、生物标志物及转化医学等领域。
经过多年的发展,益诺思目前已拥有近6万平方米的现代化设施,千余人的研究团队,分布在上海、南通、深圳、黄山等地。公司具备行业领先的国际化服务能力,与国际标准接轨,为全球医药企业和科研机构提供全方位的、符合国内及国际申报标准的一站式新药研发服务。累计为国内外600多家制药公司、新药研发机构和科研院所提供7300余项服务,助力国内创新药研发NDA成功案例13例,IND注册成功案例逾230余例,协助50余个项目获批了美国、欧盟、韩国及澳洲等国外监管机构的注册申报。
益诺思致力于为国内外客户提供一站式服务解决方案,朝着“科技创新的引领者,新药研发的加速器,生命健康的守护人”的企业愿景不断努力前进。
Shanghai InnoStar Bio-tech Co., Ltd. (InnoStar) was established in 2010 and is a subsidiary of the China National Pharmaceutical Industrial Research Institute Co., Ltd., China National Pharmaceutical Group. Adhering to the core values of "Science-orientated, Quality first, Honesty and dedication, Solidarity and mutual trust”, we strive for excellence by quality, win customers by reputation, promote development by innovation, and create benefits by management. InnoStar has successfully passed GLP inspections by US FDA and received the GLP certification from the National Medical Products Administration (NMPA), the OECD GLP certification from the Dutch GLP monitoring authority, AAALAC certification, and CAP certification from the College of American Pathologists (CAP), etc. InnoStar is a full-service, innovative drug contract research organization (CRO) with a complete global quality management system. Our business scope covers early druggability evaluation, non-clinical pharmacodynamics, non-clinical pharmacokinetics, non-clinical safety evaluation, clinical sample bioanalysis, biomarkers and translational medicine solutions.
After years of development, InnoStar now has nearly 60,000 square meters of modern facilities, more than a thousand employees in Shanghai, Nantong, Shenzhen, and other cities. InnoStar have the industry-leading international service capability, which is in line with international standards, and provide all-round one-stop new drug research and development services that compliance with domestic and international application standards for global pharmaceutical enterprises and research institutions. We have provided services for nearly 7300 projects from more than 600 pharmaceutical companies, new drug research and development institutions, and research institutes. Nonclinical studies completed in InnoStar have been used to support successful submissions of over 230 INDs and 13 NDAs/BLAs for innovative drugs in China and of more than 50 INDs to the regulatory authorities in the United States, the European Union, South Korea, and Australia, etc.
InnoStar is committed to providing one-stop service solutions for customers at China and abroad. We are striving to be the leader of technological innovation, accelerator of new drug development, and guardian of life and health.
Website:
苏州近岸蛋白质科技股份有限公司(简称近岸蛋白)深耕重组蛋白行业十余年,是一家专注于蛋白质技术与应用解决方案的高新技术企业,主营业务为生物药、体外诊断、mRNA疫苗药物、生命科学基础研究等领域的原料与技术解决方案,包括靶点及因子类蛋白、重组抗体、酶及试剂的研发、生产和销售及相关技术服务。公司在上海、苏州和菏泽建有研发、生产基地。
Website:
苏州壹达生物科技有限公司由两位国家海外高层次人才联合多位北大教授于2014年在苏州工业园区创立,是国内首家拥有完全自主知识产权的、专业研发电转染技术及其产业化产品的企业。壹达生物经多年潜心研发和稳健发展,获得市场和投资机构的肯定和支持,现拥有总共4000多平米的研发车间、GMP厂房和细胞实验室。
壹达针对科研、蛋白快速表达、细胞免疫治疗等专业应用方向开发的多款在售仪器取得了国内外客户的广泛认可,并且在核酸药物和核酸疫苗的活体递送设备及耗材上都有产品开发布局。壹达将始终秉承创新、专业、团结、用心的价值观,力争成为一家为社会创造价值的生物技术公司。
Etta Biotech is a professional electroporator manufacturer located in Suzhou, China. It was funded by 12 experts in multiple fields, including 6 PhD, 2 national experts and 4 top-university professors. Etta Biotech possesses intellectual property in electroporation technology consisting of 28 invention patents, 26 utility model patents and 3 PCT, 4 of which are US and EP patents.
Etta Biotech is the leading manufacturer of high efficiency electroporator in China, and dedicates to the development of electroporation technology to provide effective cell transfection solutions. The flow electroporator X-Porator Fl that Etta Biotech launched in Oct. 2018, enables electroporation of up to 1 x 1010 cells in one treatment to support both cell immunotherapy development and large-scale transient expression of therapeutic proteins. In the 2nd half of 2022, Etta Biotech wiII launch another flow electroporator X-Porator-M1, specifically for cell immunotherapeutic applications as its contribution to driving the next-generation cell immunotherapies from concept to clinical trials and clinical treatment.
Website:
PPC佳生集团(PPC Group)成立于1997年,是一家专注于提供药物临床研究一站式专业服务的合同研究组织(CRO),服务范围包括注册咨询、医学事务、临床监查、项目管理、数据管理、统计分析及药物安全警戒。PPC佳生集团总部位于中国上海,在中国大陆、台湾地区、韩国和日本提供全面的临床研究和实验室服务。PPC佳生集团旗下拥有1个Ⅰ期临床研究中心,4个生物分析实验室和1个中心实验室。Novotech成立于1996年,是亚太地区最大的合同研究组织(CRO)。Novotech的服务范围覆盖澳大利亚、新西兰和亚洲各地,其服务质量得到了客户和业内的认可。 2020年10月,两家亚洲领先的合同研究组织(CRO)――Novotech与PPC佳生集团(以下简称“PPC佳生”)合并成立了Novotech Health Holdings(诺威健康),旨在打造一个充分契合并具有多地域覆盖规模性的合同研究组织(CRO)平台,以满足亚洲地区快速增长的优质临床试验服务的需求。合并后的Novotech Health Holdings(诺威健康)将成为亚洲最大的生物技术专业CRO平台,可提供从首次人体到IV期临床研究的全面临床服务。Novotech Health Holdings(诺威健康)目前拥有超过2245人的国际化专业团队,在14个国家和地区拥有21个办公地点。
PPC was established in 1997 and is a subsidiary of Novotech Health Holdings ("Novotech"). Novotech is a full-service clinical CRO with labs, phase I facilities, and drug development consulting services. It has accumulated experience in over 3,700 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech Health Holdings is positioned to serve biopharmaceutical clients conducting clinical trials in Asia and globally. As of December 31, 2021, NHH had a total of 2,245 FTEs working across our offices in 14 geographies in Asia-Pacific and the United States.
Website:
江苏谱新,总部位于美丽的太湖之滨苏州市吴中区,拥有苏州总部(10000m2 GMP厂房和研发中心)、深圳和上海基地,初步形成全国布局的生产基地网络布局;美国北卡基地也在建设中,同步进行全球布局。搭建了细胞药物专用的核酸平台、悬浮无血清病毒生产平台、全封闭的细胞工艺开发平台和质控检测技术平台,打造了细胞药物从发现到产品交付的高速公路。平台已支持多个合作伙伴成功孵化了多款CAR-T、TCR-T、干细胞等药物。谱新生物致力于让更多项目更早更快地达到下一里程碑,把更多细胞药物推向市场,造福更多患者,让细胞药物谱写生命新篇章。
Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. Used by scientists and clinicians around the world, our technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, and cell culture. Almost 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer. Miltenyi Biotec has more than 2,000 employees in 28 countries – all dedicated to helping researchers and clinicians make a greater impact on science and health.
As a trusted tool provider for clinicians and industry, from large to small, CliniMACS® Systems provide technologies and instruments to the clinic. From immuno-oncology, regenerative medicine, to graft engineering, you’ll find comprehensive solutions for numerous clinical settings.
Using CliniMACS Systems, cell products have been manufactured for all stages of clinical development - from discovery to IND submission and ongoing clinical trials. We are committed to supporting investigators with solutions that enable the clinical translation and practice of novel cell and gene therapies. This support includes products and services that extend the value beyond the device and consumables.
颇尔集团(Pall Corporation)为丹纳赫集团(纽约证券交易所代码:DHR)生命科学平台旗下运营公司。颇尔全球员工团结致力于解决客户在过滤、分离和纯化方面的挑战,并促进健康、安全与环保科技的进步。颇尔提供丰富的技术和解决方案,用于保障健康、保护关键运营资产、提高产品质量以及减少排放和浪费。颇尔的生命科学和工业团队专精于服务各类行业的众多客户,包括生物技术、制药、医疗、食品饮料、实验室、微电子、航空航天、燃油石化、化工、汽车和电力等。
颇尔(中国)有限公司是颇尔集团在华独资企业,在中国历经二十多年的发展,已经由一个专注于过滤产品的公司发展为过滤、分离和纯化解决方案的专家。从上游研发到规模生产,从售前技术支持到售后服务,从产品销售到提供整体解决方案,颇尔不仅提供给客户高科技的产品和应用,更扮演着权威技术及创新品质的先锋角色。
Pall Corporation is an operating company within Danaher’s (NYSE: DHR) Life Sciences Platform. Pall associates around the world are unified by a singular drive: to solve our customers’ biggest filtration, separation and purification challenges. And, in doing so, advance health, safety and environmentally responsible technologies. Our industry-leading technologies and solutions are at work in countless applications, safeguarding health, protecting critical operating assets, improving product quality, and minimizing emissions and waste. Our Life Sciences and Industrial teams bring focused expertise to a diverse range of customers across multiple industries, including biotechnology, pharmaceutical, medical, food and beverage, laboratory, microelectronics, aerospace, fuels, petrochemical, chemical, automotive and power generation.
Pall (China) Co., Ltd., a subsidiary of Pall Corporation, has evolved from a specialized supplier of filtration products to the market leader of filtration, separation and purification solutions that serves a wide range of applications and industries after over 20 years of development in China. From R&D to manufacturing, from technical support to after-market services, from products to total solutions, Pall not only offers cutting-edge products and applications but also plays a pioneer role in leading technology, innovation and quality.
赛多利斯是国际领先的生命科学研究和生物制药行业合作伙伴。集团的实验室产品及服务板块为生物制药企业以及各类科研机构提供创新的实验室设备及产品,以满足客户开展高端科研实验和严苛的质控需求。集团的生物工艺解决方案板块提供全套的生物制药设备,并专注于一次性解决方案,帮助客户安全高效地生产生物药品和疫苗。集团营业额保持着两位数的年均增长率,并通过收购互补性技术不断扩大我们的业务范围。2020财年,集团销售额达23.4亿欧元。截止2020年,集团拥有约11,000名员工,60多个生产和销售基地,服务于全球用户。
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion.
Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them.
Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com
About Thermo Fisher Scientific China
Thermo Fisher Scientific (China) Co., Ltd has been operating in China for over 35 years. Headquartered in Shanghai, Thermo Fisher Scientific China has branch offices in Beijing, Guangzhou, Hong Kong, Chengdu, Shenyang, Xi’an, Nanjing, Wuhan, Jinan, and Dongguan with around 5,000 employees. Our products mainly include analytical instruments, laboratory equipment, chemical reagents, consumables, software and more; providing comprehensive laboratory solutions and serving customers across various industries.
In order to meet the local needs in China, we have established 8 manufacturing sites in Shanghai, Beijing, Suzhou and Guangzhou respectively. We also have 6 application centers and demo labs across the country which bring world-class technology and products with application development and training services to local customers. Lastly, we have the China Innovation Center in Shanghai and Suzhou, with over 100 scientists & engineers and more than 100 patents. China Innovation Center focuses on research and development supporting key vertical markets and develops products according to local demands with global advanced technologies. We have a nationwide maintenance network and China service training team, including over 2,800 professionals directly providing services for customers.
We are committed to enabling our customers to make the world healthier, cleaner and safer. For more information, please visit www.thermofisher.com.
赛默飞世尔科技简介
赛默飞世尔科技是科学服务领域的世界领导者。公司年销售额超过300亿美元。
我们的使命是帮助客户使世界更健康、更清洁、更安全。我们帮助客户加速生命科学领域的研究、解决在分析领域所遇到的复杂问题与挑战、促进医疗诊断和治疗的发展、提高实验室生产力。
我们全球超过80,000名赛默飞员工将借助于一系列行业领先的品牌Thermo Scientific、Applied Biosystems、Invitrogen、Fisher Scientific、Unity Lab Services和Patheon,为客户提供领先的创新技术、便捷采购方案和全方位服务。欲了解更多信息,请浏览公司网站:www.thermofisher.com
赛默飞世尔科技中国简介
赛默飞世尔科技进入中国发展已超过35年,在中国的总部设于上海,并在北京、广州、香港、成都、沈阳、西安、南京、武汉、济南、东莞等地设立了分公司,员工人数约为5000名。我们的产品主要包括分析仪器、实验室设备、试剂、耗材和软件等,提供实验室综合解决方案,为各行各业的客户服务。
为了满足中国市场的需求,现有8家工厂分别在上海、北京、苏州和广州等地运营。我们在全国还设立了6个应用开发中心以及示范实验室,将世界级的前沿技术和产品带给中国客户,并提供应用开发与培训等多项服务;位于上海和苏州的中国创新中心,拥有100多位专业研究人员和工程师及100多项专利。创新中心专注于垂直市场的产品研究和开发,结合中国市场的需求和国内外先进技术,研发适合中国用户的技术和产品;我们拥有遍布全国的维修服务网点和特别成立的中国技术培训团队,在全国有超过2800名专业人员直接为客户提供服务。
我们致力于帮助客户使世界更健康、更清洁、更安全。欲了解更多信息,请登录网站:www.thermofisher.com
ArcticZymes Technologies ASA is born from the unique conditions in the Arctic and our labs in Tromsø (Norway) where we have been developing and producing cold-adapted enzymes for more than 30 years. We are specialized manufacturer of novel and high-quality recombinant enzymes for use in molecular research, in vitro diagnostics, and therapeutics. Our high-quality enzymes are an integral part of molecular research and diagnostics, either as stand-alone enzymes or as components of kits. In therapeutics such as gene therapy and vaccine production our enzymes aide the optimization of manufacturing processes. All of our products are manufactured according to ISO13485 standards and meet all REACH requirements. The unique features of our premium enzymes are accompanied by our dedication to quality, and a no-compromises approach to collaborate with our clients and partners. ArcticZymes Technologies is trusted by leading molecular research kit manufacturers, diagnostic assay developers, contract manufacturers, and therapeutic companies around the world. We provide solutions adapted to your needs. To find out more, please visit: www.arctizymes.com
上海倍笃生物科技有限公司(以下简称“倍笃生物”),成立于2018年1月,致力于为治疗领域如细胞&基因治疗、病毒载体疫苗等,诊断领域如病原微生物检测,及类器官开发等客户提供合规、高质量物料及专业服务,以期与客户共同协作,加快研发及生产进度,为客户提供更多价值。公司代理多个品牌的试剂原料,拥有完善的质量管理体系、符合监管要求的生产标准,如cGMP规范,ISO9001、ISO13485、DMF等文件,最重要的是得到行业客户广泛的认可及使用。 作为挪威ArcticZymes Technologies的战略合作伙伴,倍笃生物负责ArcticZymes Technologies产品在中国大陆的市场宣传、技术推广及商务工作,协助厂家为CGT等行业的发展做出更多的贡献。
Website:
深圳市西尔曼科技有限公司是一家专业从事生化代谢产物快速检测的研发和生产的高科技企业,是集生化分析仪器、生物传感器研发生产、快速检测方法开发、实验室仪器销售和技术服务为一体的专业厂家。由一批长期从事于实验室分析仪器应用及技术服务的专业技术人员组建,公司长期致力于为中国的生物制药、生物制品、生物技术、食品科学、生物工程、农产品加工等行业的用户提供全球先进的仪器设备,检测技术和质量管理理念。立志为中国的生物制药、食品企业的研发和生产过程提供高性价比、高精密分析仪器和方法,降低企业日常运营成本。
在全面引进母公司的技术和设计基础上,进口主要核心部件,结合深圳的制造和人才优势在大陆进行组装和调试,进一步控制成本,提供高性价比产品。仪器技术性能居于国内领先地位,部分产品已经达到国际先进水平,完全可替代进口同类产品。为满足细胞培养和发酵对产品达到更高效、更高产能、更好的产品质量的要求,推出M-online在线生化分析仪,能够近乎实时的监测生物培养过程中的葡萄糖、乳酸、谷氨酰胺、谷氨酸、铵离子、钠离子、钾离子、钙离子(赖氨酸、乙醇、甲醇、木糖、蔗糖、半乳糖、甘油、胆碱、丙酮酸)、二氧化碳(PCO2)、溶氧(PO2)、pH等主要营养成分,为您的工艺优化、生产过程提供坚实的数据溯源。现已成功推广并应用于单抗、疫苗、氨基酸、维生素、酶制剂、IVD原料等行业,得到发酵、生物制药、生物制品、发酵饲料、大学、研究院所、疾病控制中心、体育运动等行业和部门的好评。
As a leader in contract development and manufacturing, Lonza Pharma and Biotech is recognized for our reliable, high-quality services, global capacity, innovative technology platforms, and extensive experience. Our broad capabilities span biologics, small molecules, bioconjugates, and cell and gene therapies. We manage projects from pre-clinical stage through commercialization, and our expertise covers both drug substance and drug product. We believe that the outcome – for you and your patients – can only come as a results of successful collaboration. Together, we can bring your next medicine to life.
龍沙製藥與生物技術部門, 主要在服務並提供全球合約型訂製開發與製造生產, 讓相關製藥與生物技術公司可以爲病人帶來所需藥物.
從基因到最終藥物產品, 我們所提供的解決方案, 旨在簡化客戶的外包流程, 並滿足客戶所預期的可信結果.
我們的服務經驗十分廣泛, 包括新創性療法的商業化與各種藥物的製造. 我們將持續投資, 來解決當前的問題, 更為了幫客戶戰勝未來的挑戰.
我們將齊心協力, 期待爲您帶來全新的藥物.
Website:
Innoforce enables the innovation and global supply of plasmid DNA, mRNA, cell & gene therapeutics, powered by a world-class manufacturing & development hub.
With extensive expertise in process development and manufacturing of Advanced Therapy Medicinal Products (ATMPs), Innoforce can be a trusted partner for your innovative ATMP projects from R&D through commercialization.
Website:
源健优科生物科技(上海)有限公司成立于2021年,在中国上海与美国马里兰均设有GMP Site。公司专注于细胞与基因治疗领域的CDMO创新 4*4服务模式,即4大技术平台(质粒、病毒、细胞和mRNA),为4类项目阶段类型(R&D、PD/AD、GMP和IND/BLA filing)的产品提供一站式服务。立足于连续创新优化的技术平台,源健优科可提供临床前研究支持,符合行业标准的工艺设计和开发,保障品质的临床试验和商业化生产,符合IND/CTA/BLA的CMC申报材料的全流程服务。源健优科在具有数十年细胞与基因治疗领域CMC和GMP生产经验的核心团队带领下,建立了完善的质量管理体系,为全球客户提供安全稳定的供应链,灵活地满足客户的各种服务需求。
Forecyte Bio (Shanghai) Co., Ltd was founded in 2021, and our GMP site is located in Shanghai, China and Maryland, USA. We focus on the CDMO innovative 4*4 service model in the field of cell and gene therapy, which provides a one-stop service for 4 types of project stages (R&D, PD/AD, GMP and IND/BLA filing) products by 4 major technology platforms (plasmid, virus, cell and mRNA). Based on the continuous innovative optimized technology platform, we could provide full process services to meet the preclinical research support, process design and development with industry standards, high-quality clinical trials and commercial production, and application materials complied with IND/CTA/BLA CMC. Under the leadership of a core team with decades of CMC and GMP production experience in the field of cell and gene therapy, Forecyte Bio established a complete quality management system to provide a safe and stable supply chain for the global customers and meet their diverse service demands flexibly.
Website:
金斯瑞蓬勃生物是金斯瑞的生物医药合同研发生产组织(CDMO),拥有一站式生物药研发生产平台,致力于为抗体药物及基因和细胞治疗药物提供从靶点开发到商业化生产的端到端服务。一站式抗体药开发解决方案涵盖抗体药发现、抗体工程和抗体评价等抗体药服务。在抗体药临床前药学开发方面,金斯瑞蓬勃生物提供细胞系开发、宿主细胞商业化授权、上下游工艺开发、分析方法开发和临床样品生产等一体化CDMO服务加速IND进程。基因细胞治疗整体解决方案涵盖了非注册临床、工艺开发,注册临床和商业化全阶段质粒病毒生产。
金斯瑞蓬勃生物始终以“合作加速创新”为理念,帮助客户缩短生物药进入临床的时间,显著降低客户研发成本,加速医药转化。
GenScript ProBio is the biologics CDMO segment of GenScript, proactively providing end-to-end service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in antibody drug and gene and cell therapy to accelerate drug development for customers.
GenScript ProBio’s innovative solutions for antibody drug development include antibody drug discovery (hybridoma, antibody library, fully human transgenic mice, bispecific antibodies technologies, single b cell screening technology), antibody engineering (antibody humanization, affinity maturation, Fc Engineering) and antibody characterization (analytics and bioassays). In terms of biologics development service, GenScript ProBio has built a regulatory-compliant platform, from stable cell line development, host cell license, process development, analytical development to clinical manufacturing services, providing fed-batch and perfusion process to accelerate IND process and high quality material for clinical trials. GenScript ProBio has successfully delivered multiple CMC and GMP manufacturing projects.
GenScript ProBio’s innovative solutions for antibody drug development include antibody drug discovery (hybridoma, antibody library, fully human transgenic mice, bispecific antibodies technologies, single b cell screening technology), antibody engineering (antibody humanization, affinity maturation, Fc Engineering) and antibody characterization (analytics and bioassays). In terms of biologics development service, GenScript ProBio has built a regulatory-compliant platform, from stable cell line development, host cell license, process development, analytical development to clinical manufacturing services, providing fed-batch and perfusion process to accelerate IND process and high quality material for clinical trials. GenScript ProBio has successfully delivered multiple CMC and GMP manufacturing projects.
GenScript ProBio’s total gene and cell therapy solution covers CMC of plasmid and virus for IND filing as well as clinical manufacturing and commercial manufacturing. Our quality management systems ensure phase appropriate compliance, data integrity and traceability. Toward the mission of “Innovation through Collaboration”, GenScript ProBio is committed to helping customers shorten the timeline for the development of biological drugs from discovery to commercialization, significantly lowering R&D costs and building a healthier future.
Website:
苏州博腾生物制药有限公司成立于2018 年12月,立足于苏州工业园区,以上市公司-重庆博腾制药科技股份有限公司(股票代码:300363)为依托,搭建了质粒,病毒载体和细胞治疗产品为一体的CDMO 平台,提供从早期研究、研究者发起的临床、新药临床试验申请(IND)、注册临床试验样品和商业化生产服务,加快药物研究转化进程。
博腾生物聚焦基因与细胞治疗,在博腾股份的成功经验之上,以国际一流的专业人才为核心,秉承“客户第一”的服务宗旨,以“合规、专业、专注、开放协作”为品牌理念,延续母公司强大的IP保护和项目管理机制以及完善的质量管理体系,充分利用核心团队将基因和细胞治疗产品推向临床直至上市的成功经验,为全球客户提供优质和高效的服务,让好药更早惠及大众。
Porton Biologics Ltd. (Portonbio) was established in 2018. Located in Suzhou Industrial Park, and as a subsidiary of Porton Pharma Solutions Ltd, PortonBio provides Gene and Cell Therapy CDMO service for innovators from the early stage, IND filling and even commercial production.
Based on the successful experience of Porton Pharma Solution Ltd, Portonbio will take the international team as the core, adhere to the service concept of “Customer First and Excellence Always”, and take full advantage of high-level technology and equipment to create high-end biological and CDMO platform. Portonbio pursues to become a reliable partner for global pharmaceuticals and biotech companies.
Website:
宜明(北京)细胞生物科技有限公司(简称:宜明细胞)成立于2015年10月,是一家致力于基因治疗和细胞治疗技术的开发和应用、能够为基因治疗产业化提供整体解决方案的研发生产型生物技术公司。宜明细胞专家团队为来自美国国立卫生研究院癌症研究所、哈佛大学、霍普金斯大学、马里兰大学、加拿大哥伦比亚大学(UBC)等国际知名院校的教授和研究员,在细胞治疗及基因治疗领域拥有十余年的产业经验。 宜明细胞已建成的济南基地GMP厂房面积达2600㎡,洁净度达到C+A标准,灌装采用绝对A级隔离,并邀请了GMP体系专家全职进行GMP体系建设,按照法规要求建有独立的质粒生产平台、病毒包装平台、细胞培养平台、细胞库平台等,并拥有涵盖生化、微生物、化学的质量检测平台,并实现完全的物理隔离,各平台拥有独立通风系统,全面降低交叉污染的风险。 宜明细胞即将于2021年建成投产的苏州基地GMP新厂房面积达9000㎡,全方位提高GMP级质粒、慢病毒、AAV、腺病毒等产品的产能,全面服务整个行业。 我们邀请了 GMP 体系专家进行 GMP 体系建设,全方位确保为您生产的临床用质粒、临床用病毒等产品符合基因 治疗 IND 申报及新药申报的 GMP 法规要求,降低新药研发的成本、加快新药上市的进度。 宜明细胞定位于生物与健康产业,坚持以成为生物医药的引领者、生命科学的推动者为使命,以推动研发国人用 得起的新型生物药为己任,让包括基因治疗和细胞治疗的药物惠及更多的患者。
Website:

查士利华微生物应用技术(上海)有限公司是Charles River的全资子公司,致力于为客户提供尖端的微生物应用技术,以满足制药、家居、个人护理行业多样化需求。我们独一无二的Endosafe®内毒素检测,Celsis®快速微生物检测和Accugenix®微生物鉴定三大品牌业务组合,确保您的生产运营高效,顺畅,降低生产成本,保护公司声誉。
Charles River Microbial Solutions (Shanghai) Co., Ltd. is the subsidiary of Charles River Laboratories Inc. The Microbial Solutions portfolio from Charles River brings you progressive products and services that deliver accurate, relevant, and reliable data to fuel confident decisions on product quality and contamination control. Our unique combination of Endosafe® endotoxin testing, Celsis® rapid microbial detection, and Accugenix® microbial identification and strain typing keeps your manufacturing operations running efficiently and smoothly, lowers your cost to manufacture, and protects your reputation.
序祯达生物科技是中国领先的多组学研究和临床服务提供商,致力于基因组学、蛋白组学和其他相关服务。本着以研究为首任,以客户为中心的宗旨,支持药物研发企业进行药物筛选、生物标记物发现和临床试验。 序祯达生物科技提供按照CLIA/CAP标准验证的多样化基因组学和蛋白组学检测,包括基因分型和基因表达qPCR检测,NGS检测和蛋白质生物标志物检测。
其中最具特色的检测包括FoundationOne CDx、用于组织和ctDNA的Illumina TSO500、10x Genomics单细胞解决方案、Olink Target 96/48、Olink Explore 1536/384,及宏基因组、mRNA、smRNA、全基因组和外显子组测序等,并可根据项目需求提供定制化检测
Website:
Mission Bio is a life sciences company that accelerates discoveries and cures in oncology by equipping researchers with the tools they need to improve how we measure and predict our resistance and response to cancer therapies. Mission Bio’s multi-omics approach improves time-to-market for new therapeutics, including innovative cell and gene therapies that provide new pathways to health. Founded in 2014, Mission Bio has secured investment from Novo Growth, Cota Capital, Agilent Technologies, Mayfield Fund, and others.
The company’s Tapestri Platform gives researchers around the globe the power to interrogate every molecule in a cell together, providing a comprehensive understanding of activity from a single sample. Tapestri is the only commercialized multi-omics platform capable of analyzing DNA and protein simultaneously, from the same sample at single-cell resolution. The Tapestri Platform is being utilized by customers at leading research centers, pharmaceutical, and diagnostics companies around the world to develop treatments and eventually cures for cancer and other rare diseases. To learn more, visit missionbio.com.
恺佧生物(Kactus Biosystems)是一家以研发为驱动的创新型蛋白抗体类国际化生物高科技公司,主要专注于免疫治疗和诊断市场。专属的新型功能重组蛋白和抗体研发生产平台 (Structure Aided Design and Multiplex Screening ,SAMS™), 服务于全球创新药研发企业客户,提供基于结构设计的功能靶点蛋白,包括膜蛋白及展示其功能结构域和表位的重组蛋白,通过独特的技术及生产体系,高效率、高成功率地解决和突破技术困难,满足了客户的需求。
Kactus Biosystems was founded in Shanghai, China, and strives to be a world-class biotech company to serve global biopharma and diagnostics customers.
● We focus on delivering protein and antibody products and technologies for immune therapy and IVD customers
● We have innovative product development strategies and world-class commercial operations We are solving unmet needs for antigen protein in drug discovery
● Bioactivity Issue: No bioactivity / No activity on cell based assay
● Batch-to-Batch Consistency
● Poor Immunogenicity
● Unavailable, Commercial Antigens: Transmembrane Proteins: GPCR, CD20, etc.
● Cost Effective, Highly Bioactive Enzymes: Capping Enzyme (mRNA transfection & therapeutics)
● Protein / Antibody Engineering Consultation
上海外高桥生物医药园——自贸壹号生命科技产业园(Simbay Park),是星北集团(Simbay Group)旗下专注于医疗企业孵化培育转化的创新服务型产业园。园区依托天然的【自贸+保税】外向型经济区域优势,以合理的空间配置、优美的自然环境及独特的生物医药产业服务,聚焦创新药物、生物技术及创新疗法、高端医疗器械等领域的研发、转化与制造,打造了独特的生物医药“CRO+CDMO+CSO+Capital+CHO(人力资源)+CMO(品牌营销)+EHS(合规管理)”全方位服务平台。园区总规划面积50万平米,一期10万㎡已开放,近100家生物科技创新项目已入驻,现已发展成为新兴国际化生物医药生态园区,为辉大基因、星奕昂、西湖生物、晶泰科技、齐鲁干细胞、维通利华等代表企业创造了高价值及服务。
深研生物是一家生物技术与自动化技术深度结合的研发型企业,专注于细胞治疗和基因治疗领域中的核心技术与核心工艺的研究。
公司使命:利用多学科与生命科学的交叉融合,完成细胞治疗及基因治疗中一系列核心技术与工艺的研发,并推动生物技术研发进入自动化、信息化时代。
公司愿景:提供成本可控、稳定可靠的高度自动化、精准化、个体化的癌症免疫治疗整体解决方案。
公司有三大技术研发平台,包括自动化设备研发平台、生物技术研发平台、生物自动化研发平台。
自动化设备平台核心产品CellSep PRO是国产唯一上市的全封闭自动化细胞处理系统,适用于多种细胞治疗产品的标准化生产,包括CART、TCR-T、NK、骨髓干细胞等。
生物技术平台核心产品EuLV系统是全球首家研发,使用稳定生产细胞株生产慢病毒载体的技术平台,利用EuLV系统生产慢病毒载体的效率是普通慢病毒载体制备方法100-400倍,可在提高病毒载体质量和产量的同时大幅降低制备成本。
Eurekabio is an R&D enterprise which biotechnology combines with automation technology. Eurekabio focuses on the research of core technology and craft from the field of cellular and genetic therapy.
Our goal: The using of life science and multiple subject intercross-amalgamation achieve cellular and genetic therapy including core technology and craft study. Moreover, this intercross-amalgamation promotes biotechnology research into the era of automation and information.
Our vision: supporting an approach of cancer immunotherapy which is controllable cost and stability in the high level of automation, accretion and individuation.
Eurekabio has three main technologic types of research and development including automation equipment, biotechnology, and biomation. CellSep PRO, an automation product, is the only one automated fully enclosed cellular processing system on the Chinese market. CellSep PRO uses in the standardized production of multiple cellular therapies including CART, TCR-T, NK and bone marrow stem cells, etc.
EuLV system, the first biotechnology product in the world, used technology to produce cell strain and lentivirus vector stability. The production of lentivirus vectors in the EuLV system is more 100-400 times efficient than that in standard condition. Furthermore, EuLV system does not only improve the quality and quantity of virus vectors, but also reduce preparation cost significantly.
CPC - Colder Products Company, is the leader in single-use connection technology offering a wide variety of cell and gene therapy connection solutions that ensure ease of use and a robust connection. Single-use technologies (SUT) saves time and labor during set-up and between cycles, by eliminating steps, costs of cleaning, sterilization; and eliminating cross-contaminations between batches. CPC connectors have been tested and validated to comply with accepted industry standards; for mechanical strength; extractables and leachables; bacterial ingress and others. Learn more about the AseptiQuik connectors and our entire portfolio at cpcworldwide.com/cgt to help you to connect with confidence.
云舟生物科技(广州)有限公司创建于2014年3月,是一家集研发、生产及线上销售基因载体的创新型公司,主营业务为基因载体构建产品和相关衍生产品(其中包括病毒包装、蛋白表达纯化等业务 )及技术服务,以及基于基因治疗临床药物的CDMO业务,涉及全线的工艺开发及生产过程,技术领域涵括分子克隆、细胞生物、蛋白表达纯化及生物信息等。云舟生物自主开发出全球第一款基因载体免费智能设计平台——VectorBuilder( www.vectorbuilder.cn),即“载体家”,实现了基因载体构建技术的商业化及规模化生产,为广大科研学者提供标准化的基因载体构建服务。云舟生物立足中国,面向全球,将携手全球每一个科研机构、生物制药公司共同致力于基因治疗药物研究,让基因药物治疗不再是奢望。
As a global pioneer in custom DNA vectors and recombinant viruses, VectorBuilder’s revolutionary online-to-offline (O2O) platform provides a powerful one-stop solution to all the vector and virus needs in the life sciences. VectorBuilder has a wide spectrum of offerings, including: Vector design, Custom cloning, Virus packaging, Library construction, BAC recombineering, Mutagenesis, Stable cell line generation and more. Additionally, our state-of-the-art GMP facilities provide GMP-grade vector manufacturing for a wide range of clinical applications. VectorBuilder has delivered hundreds of thousands of custom vectors and recombinant viruses to tens of thousands of researchers in universities and companies across the world, and has received numerous citations in high-impact scientific publications. VectorBuilder’s highly innovative online platform that combines sophisticated yet intuitive vector design capabilities with streamlined online ordering has won multiple awards. Since our initial market launch in 2014, VectorBuilder has grown at an explosive pace to become the world's largest provider of custom vectors and recombinant viruses. Try VectorBuilder (www.vectorbuilder.cn) today and supercharge your research!
PackGene Biotech, as an international AAV packaging supplier (one of the largest in the world), started up in Massachusetts. PackGene focuses on services of the rAAV-based gene therapy CDMO-from plasmid to rAAV in clinical-grade, rAAV packaging in research-grade, lentivirus packaging, vector cloning, etc. Our services aim to provide efficient, cost-effective, high-quality viral delivery solutions for gene and cell therapy, as well as clinical trials at various scale levels. PackGene has been building up its reputation by First-class Quality · Efficient Supply · Assured Service.
派真生物是一家专注于基因治疗载体生产与服务的国家高新技术企业,一直以“让老百姓用得起基因治疗”作为公司使命,以基因治疗研发与产业化过程中的挑战——“rAAV血清型开发、病毒包装及GMP规 模化生产”作为业务引擎,以稳定、高效、经济的特色服务与技术服务加速全球范围内基因与细胞治疗开发、临床研究与商业化进程,打造具有全球影响力的基因治疗明星技术品牌!公司建立了高水平病毒载体开发与规模化生产平台,在快速、高纯度、高滴度、高感染力的 rAAV生产及病毒包装方面拥有核心知识产权,在载体构建、病毒包装、临床级质粒和AAV生产上积累了丰富经验,熟悉FDA、ICH和NMPA等对基因疗法制品的规范要求。
广东君厚生物医药有限公司是国内首批提供生产级(GMP级)逆病毒载体和细胞免疫治疗CDMO整体解决方案的公司。本公司拥有建立GMP生产平台的专业核心团队和全套核心技术,主要生产GMP级别的所有基因工程细胞免疫治疗领域的关键制剂,面向国内所有从事CAR-T、TCR-T、细胞治疗和基因编辑等类型的科研院校、医疗机构、研究机构、医药企业,提供细胞免疫治疗CDMO服务的整体解决方案,包括CAR-T细胞免疫产品病毒载体的定制、开发、GMP生产服务等。
法罗斯疫苗(“法罗斯”)株式会社是一家具有开拓精神的生物科技创新公司,利用法罗斯先进的技术平台,尖端灵活的设备设施和专业团队,致力于开发针对人类肿瘤和难以治愈性疾病的创新性生物疗法。 法罗斯基于包括细胞工艺,慢病毒载体系统(CAR-T*/TCR-T*)和蛋白质工程等技术平台,专注开发针对各种肿瘤和难以治愈性疾病的细胞和基因疗法。
法罗斯是利用肿瘤特异性T细胞、嵌合抗原受体T细胞和树突细胞等基因细胞疗法治疗各种癌症和难治疾病如:白血病、淋巴瘤、肝癌、急性心肌梗死(AMI)后的心力衰竭等先进的生物药物商业化先锋。
从长远来看,法罗斯有着清晰的、令人信服且可实现的愿景,即“作为全球细胞和基因治疗与疫苗领域的领导者,打造生物制药行业新典范”。 为了实现这个愿景,法罗斯正沿着正确的轨道前进,并确立了三大战略:一是通过成功募集资金来激发公司未来的增长动力;二是建立,启用了拥有先进仪器设备的全新研发中心和GMP生产平台;并以不懈的努力,与全球法罗斯的合作伙伴一起推动CAR-T疗法的IND和NDA。
Pharos Vaccine is a pioneering BIO venture company, leading the development of innovative biotherapeutics for human cancers and incurable diseases with relevant platform technologies, state-of-the-art and flexible facilities, equipment and human capabilities.
Pharos Vaccine concentrates on the development of cellular and gene therapy for various cancers and incurable diseases on the platform technologies including Cell Processing, Lentiviral Vector System (CAR-T* & TCR-T**) and Protein Engineering. Pharos Vaccine is pioneering the way of commercialization of cutting- edge biomedicines, in which genetic cell therapy represents, for curing various cancers and incurable diseases including leukemia, lymphoma, liver cancer, heart failure post AMI by using tumor-specific T-cells, chimeric antigen receptor T-cells and dendritic cells.
Long-term wise, Pharos Vaccine has a clear, compelling and achievable vision of ‘Lighting the New Paradigm of Vaccine as Global Leader in Vaccine and Therapies’. To realize the vision, Pharos Vaccine is going on the right track with three strategic pillars – one is to trigger developing company’s future growth drivers by successfully gaining needed funds, the other is to relocate to the new office building with own GMP facility and equipment set up, and the last one is to complete filing for IND of CAR-T therapy within the year and afterwards acquire NDA of the therapy in Korea in a relentless manner.
Website:
上海曼博生物医药科技有限公司成立于2019年,致力于将全球领先的创新产品和前沿技术带入中国,帮助国内科研工作者在第一时间接触世界范围内的技术革命,并分享研发工具的进步带来的技术红利。
依托于母公司和兄弟公司深厚的资源和超过1400家的国内优质客户群体,生命科学领域的一站式供应链体系,以及高风险生物危险材料进出口平台的优势,曼博生物严格筛选国际创新且经过同行验证过的产品和技术,引入中国市场,开发、孵育和推广。
上海曼博生物医药科技有限公司,集中在为肿瘤/免疫,抗体药物研发,干细胞/细胞治疗/基因治疗领域客户提供尖端小众创新产品,包括提供商业授权灵活的CHO工程细胞株,以支持抗体药物商业化生产;以及提供从Research grade到cGMP等级的非动物源培养基质,基因编辑工具,病毒载体,转染试剂,病毒转导试剂等产品和定制服务,支持ATMP(Advance Therapy Medicinal Products)药物研发从R&D到Clinical trial以及后期商业化的无缝转化。
Sartorius Stedim Biotech is a leading international provider of integrated solutions for the biopharmaceutical industry. With our extensive portfolio of products, technologies and services, we cover wide areas of the biopharmaceutical process chain, ranging from fermentation, cell cultivation, filtration and purification to media storage and transportation. In process filtration, fermentation and fluid management, our company holds leading positions in the markets it serves across the globe. Our single-use products that have meanwhile become established in nearly all process steps are playing an increasingly important role in the manufacture of biopharmaceuticals. As a result, we help our customers produce biological medications and vaccines safely and efficiently.
Beckman Coulter Life Sciences is dedicated to improving the health of people around the world. The company’s global leadership and world-class service and support delivers sophisticated instrument systems, reagents and services to life science researchers in academic and commercial laboratories, enabling new discoveries in biology-based research and development. A leader in centrifugation and flow cytometry, Beckman Coulter has long been an innovator in life sciences instruments and solutions used at the forefront of important areas of investigation, including genomics, proteomics and cellular research.
Website:
同腾睿杰(上海)生物科技有限公司是一家专业的生命科学仪器销售的公司,是上海同腾生物科技有限公司的兄弟公司,主要服务于生命科学、生物制药和免疫肿瘤领域,客户主要为高等院校、药物研究所、制药企业等。自公司成立以来,凭借先进的软硬件基础及丰富的行业实践经验,为相关领域的研究人员提供国际上最前沿的实验室成套设备,满足各类科学研究的需求。
Website:
MCE 致力于为全球客户提供新颖齐全的高品质小分子活性化合物。30000 多种特异性抑制剂、激动剂作用于表观遗传学、PI3K/Akt/mTOR、凋亡、MAPK、Wnt 等 20 个信号通路的 500+ 个靶点蛋白,覆盖癌症、神经科学、免疫学等热门疾病研究领域。MCE 的 100 多种活性化合物库,包含 15000 多种具有生物活性的小分子化合物,可用于 高通量筛选 (HTS) 和 高内涵筛选 (HCS),是进行新药筛选和新适应症发现等研究的专业工具。MCE 拥有众多全球独家化合物,并有专业团队追踪新的制药及生命科学研究进展,能够为您提供新近研究的活性化合物,以满足您的科研需求。
关于安捷伦
安捷伦科技有限公司(纽约证交所:A)是生命科学、诊断和应用化学市场领域的全球领导者,致力于为提升人类生活品质提供敏锐洞察和创新经验。安捷伦的仪器、软件、服务、解决方案和专家能够为客户最具挑战性的难题提供更可靠的答案。2020财年,安捷伦营业收入为53.4亿美元,全球员工数约为16,400人。
Marken is a wholly owned subsidiary of the UPS Healthcare division. With Polar Speed and Marken included, the UPS Healthcare division staffs 128 locations with 5500 employees worldwide. Marken offers a state-of-the-art GMP-compliant depot network and logistic hubs for clinical drug product storage and distribution in 56 locations worldwide, while maintaining the leading position for Direct to Patient and Home Health care services, biological sample shipments and biological kit production. Marken’s dedicated 1300 staff members manage 85,000 drug product and biological sample shipments every month at all temperature ranges in more than 220 countries. Additional services such as ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy add to Marken’s unique position in the pharma and logistics industry.
Website:
上海(南翔)精准医学产业园是创新型政产学研产业化平台。产业园围绕精准诊断、精准治疗、精准康复、精准预防四大核心领域,以专业化、市场化和国际化的运营机制汇聚全球精准医学创新创业资源,构建“精准医学产业化研究院”、“精准医学产业转化平台”、“精准医学临床应用平台”、“上海精准医学产业投资基金”四位一体的创新生态系统,打造全球精准医学产业化新高地,成为精准医学创新成果转化地、创新主体集聚地和创新要素集散地,代表上海和中国参与全球在精准医学领域的竞争。
BioDuro-Sundia, an Advent International portfolio company, is a leading contract research, development and manufacturing organization (CRDMO) that provides biopharmaceutical partners with fully integrated services to support drug discovery, development and manufacturing for both drug substance and drug product. The company is the industry’s third largest, with major operations in China and the US—featuring more than 2,000 employees and 10 global sites.
Core expertise includes small and large molecule discovery, development and scale up, support for IND submission, and unique technology platforms such as bioavailability enhancement of insoluble compounds. The company has research sites, as well as GMP manufacturing facilities in both China and the US. The one-stop-shop operation helps biopharma partners across the globe to significantly accelerate discovery and de-risk development to create higher value outcomes.
保诺-桑迪亚,安宏资本旗下投资企业之一。保诺-桑迪亚是一家领先的合同研究、工艺开发和生产公司(CRDMO公司),专业为生物制药客户提供全面整合服务,支持药物的发现、开发和生产,包括原料药和制剂。作为世界第三大CRDMO公司,保诺-桑迪亚在全球10大分支机构拥有超过2,000名团队成员,在中国和美国开展其主要业务。
保诺-桑迪亚在大小分子发现、开发和放大方面有深厚而丰富的专业知识,支持IND申报,拥有独特的专利技术平台(例如难溶化合物生物有效性增强平台)。公司在中国和美国均设有研发中心和生产基地。保诺-桑迪亚“一站式”运营模式,有效帮助生物制药客户加快发现和降低开发风险,从而创造更高的价值。
Website:
Johnson Matthey Pharmaceutical Services (Yantai) Co., Ltd is a 100% holding company of Johnson Matthey Group, and is a part of our Innovator business unit in Health Sector. Along with the JM global network in Pharma Services, Chiral Technology and API business, JM Yantai site has an established a strong team in R&D and management based on easily accessible raw material and sufficient talent pool which allow us to supply tailored technology, process R&D services, advanced intermediate and API production for high-end innovator pharmaceutical clients.
明捷医药是一家提供一站式的药物质量研究及生产放行解决方案的第三方技术服务公司。在南京药谷、上海张江药谷、上海国际医学园区分别设有独立的质量控制实验室,面积共5000多平方米。明捷医药参照cGMP和CNAS质量体系建立了支持药品注册申报及生产放行的一体化药物质量控制实验室,为客户提供符合全球药政法规的药物质量研究、基因毒杂质研究、包材相容性研究、元素杂质研究、生物药工艺残留物研究、原料药备案、注射剂一致性评价等多项技术服务。
公司秉承“专业、创新、合作、责任”的理念,不断加强能力建设、质量体系建设及人才队伍建设,以专业的技术团队和合规的质量体系为客户提供高效率、高质量、合规的技术服务,一起为医药事业和人类健康而努力。
Milestone Pharma is a third-party technical service company that provides one-stop solutions for drug quality research and product release testing services. Milestone Pharma has three independent quality control laboratories in Nanjing Medicine Valley, Shanghai Zhangjiang Medicine Valley and Shanghai International Medical Zone , covering a layout area of more than 5,000 square meters. Milestone Pharma has established an integrated drug quality control procedures to support drug registration application and drug product release in compliance with cGMP and CNAS quality systems. We provide technical services including drug quality study, genotoxic impurity study, packaging material compatibility study (extractables and leachables), elemental impurity study, biological drug process residue study, DMF filing, generic drug consistency evaluation in compliance with global drug regulations.
Adhering to the concept of "specialty, innovation, cooperation and responsibility", we continuously strengthen on the improvement of capability, quality system and talent teams. We aim to provide customers with efficient, high-quality and well-compliant technical services with professional technical teams and GMP quality system.The quality of human health and pharmaceutical industry, we care and endeavor!
HitGen is a rapidly growing biotech company with headquarters based in Chengdu, China, with a subsidiary in the USA. HitGen has established an industry-leading platform for early-stage drug discovery research centred on DNA encoded chemical libraries (DELs). HitGen’s DELs include encoded syntheses for hundreds of billions of novel, diverse, drug-like small molecule and macrocycle compounds. These compounds are members of DELs synthesised from many hundreds of distinct chemical scaffolds, designed and assembled with tractable chemistry based on proven results for identifying drug-like leads against biological targets from known and novel classes. HitGen is working with multiple pharmaceutical and biotech companies, foundations and research institutes in North America, Europe and Asia to discover and develop novel therapeutics of the future.
Website: www.porton.cn
Website:www.cas.org
Website: www.e-3.com
Website: www.tzcmc.net
EVs and Advanced Therapies Summit 2023  |  Telephone: +86 21 6157 7321  |  E-mail: kevin.tan@deliver-consulting.com
© Extracellular Vesicles and Advanced Therapies Summit 2023- All rights reserved